WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock Ownership - Who owns Dianthus Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Dianthus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Simon ReadDirector2026-08-192,778$18.36
$51.00kBuy
Simon ReadDirector2026-08-192,778$117.55
$326.55kSell
Adam M. VenessCLO;Sec;SVP2026-08-1315,000$18.17
$272.55kBuy
Simon ReadDirector2026-08-10831$108.95
$90.54kSell
Simon ReadDirector2026-08-10272$109.96
$29.91kSell
Anne McGeorgeDirector2026-08-101,800$109.30
$196.74kSell
Anne McGeorgeDirector2026-08-101,000$110.64
$110.64kSell
Anne McGeorgeDirector2026-08-10700$111.41
$77.99kSell
Anne McGeorgeDirector2026-08-101,250$19.36
$24.20kBuy
Anne McGeorgeDirector2026-08-106,500$11.20
$72.80kBuy

1 of 10

DNTH insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DNTH insiders and whales buy or sell their stock.

DNTH Shareholders

What type of owners hold Dianthus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC14.60%8,164,219$910.64MInsider
Bruce Booth7.36%4,117,125$459.22MInsider
Gv 2016 GP LLC5.97%3,339,137$372.45MInsider
Blake Byers5.97%3,339,137$372.45MInsider
Atlas Venture Fund X LP5.63%3,148,399$351.17MInsider
Third Rock Ventures IV LP5.47%3,058,204$341.11MInsider
Lei Meng4.86%2,717,554$303.12MInsider
Leon O. Moulder Jr.2.57%1,436,745$160.25MInsider
Atlas Venture Opportunity Fund I LP2.23%1,250,000$139.43MInsider
Jason Gardner1.69%944,954$105.40MInsider

1 of 3

DNTH vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DNTH0.12%60.34%Net BuyingNet Buying
BLTE0.02%0.73%Net SellingNet Selling
PTCT0.12%18.88%Net SellingNet Selling
COGT0.11%8.01%Net Selling
XENE0.10%2.58%Net SellingNet Selling
View Top Biotech Stocks

Dianthus Therapeutics Stock Ownership FAQ

Who owns Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ: DNTH) is owned by 0.12% institutional shareholders, 60.34% Dianthus Therapeutics insiders, and 39.55% retail investors. Fairmount Funds Management LLC is the largest individual Dianthus Therapeutics shareholder, owning 8.16M shares representing 14.60% of the company. Fairmount Funds Management LLC's Dianthus Therapeutics shares are currently valued at $864.10M.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.